top of page
Join Humimic in modernizing drug development with
organ-on-chip technology
Patent-protected technology
Razor-and-blades recurring revenue model
Existing beta users and validation data
Strong regulatory tailwinds supporting organ-on-chip adoption
Large acquisition-driven exit landscape
Interested in learning more or participating in our $1.5M pre-seed round opening in October 2026? Download our investor materials and request a meeting.
Problem
90% of drugs fail clinical trials, largely due to poor predictive power of traditional preclinical models, like animals.
Market
opportunity
The organ-on-chip market is projected to reach $498M by 2028, driven by regulatory and industry shifts toward human-relevant testing.
Solution
Patented organ-on-chip platforms - including heart, brain, muscle, and nasal airway - with integrated sensing provide real-time, human-relevant drug response data. Safer drugs making it to market 2 years faster and for $250M less per approved drug.
95% lower equipment cost, automated data collection, and seamless integration into laboratory workflows.
Competitive advantage
Team
Founded by industry-recognized innovators with expertise spanning organ-on-chip engineering, commercialization, and drug development.
Traction
$4.9M in technology funding, $100K business development funding, 300+ conversations with customers guiding our decisions, 7 beta testing labs, 4 patent families, and international recognition (Forbes Science, Nature, National Academy of Inventors).
Interested in participating in our pre-seed round?
Humimic Biosystems is raising $1.5M to establish manufacturing capabilities, expand pharmaceutical pilot programs, and accelerate commercialization.
This round is expected to open in October 2026.
Questions? Contact our CEO, Lexi Applequist, directly.
bottom of page